EDIB KORKUT, MD
Osteopathic Medicine in Alexandria, LA
License number
Louisiana 013119
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
2495 Shreveport Hwy, Alexandria, LA 71306
4977 Battery Ln, Bethesda, MD 20814
4977 Battery Ln, Bethesda, MD 20814
Phone
(318) 473-0010
(301) 215-4877
(301) 215-4877
Personal information
See more information about EDIB KORKUT at radaris.comName
Address
Phone
4977 Battery Ln APT 317, Bethesda, MD 20814
Chevy Chase, MD
4977 Battery Ln, Bethesda, MD 20814
Professional information
Dr. Edib Korkut, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
4977 Battery Ln SUITE 317, Bethesda 20814
(301) 215-4877 (Phone)
INLAND HOSPITAL
200 Kennedy Memorial Dr, Waterville 04901
(207) 873-0731 (Phone), (207) 861-3039 (Fax)
(301) 215-4877 (Phone)
INLAND HOSPITAL
200 Kennedy Memorial Dr, Waterville 04901
(207) 873-0731 (Phone), (207) 861-3039 (Fax)
Languages:
English
Edib Korkut, Bethesda MD
Specialties:
Internist
Address:
4977 Battery Ln, Bethesda, MD 20814
Protection Of Hematopoietic Cells By The Induction Of Post-Mitotic Quiescence
US Patent:
2001003, Nov 8, 2001
Filed:
Jun 18, 2001
Appl. No.:
09/881669
Inventors:
Edib Korkut - Bethesda MD, US
International Classification:
A61K038/00
US Classification:
514/002000
Abstract:
Methods for minimizing the toxic effects of chemotherapy or cytotoxic irradiation on the hematopoietic cells of a patient having neoplastic cells or a malignant tumor are provided. Methods of the invention comprise the steps of treating the patient with a dosage of at least one hematopoietic cell stimulating factor, the dosage being sufficient in amount and time to cause a substantial increase in the population of the hematopoietic cells, and in differentiated blood cells, and then treating the patient with a dosage of chemotherapeutic agents or cytotoxic irradiation sufficient to substantially reduce the population of neoplastic or cancerous cells. The methods increase the absolute number of hematopoietic progenitor cells and differentiated cells in the patient's blood system prior to the administration of therapeutic insult thereby increasing the number of hematopoietic progenitor cells and differentiated cells which survive therapeutic insult.